Background Acute myeloid leukemia (AML) is a heterogeneous form of cancer, and it is one of the dominant causes of malignancy-related mortality in patients younger than 35 years old. Therefore, the treatment must be selected based on risk stratification. However, the methods to predict the clinical outcomes of AML are insufficient. Long non-coding RNAs (lncRNAs) are unable or barely able to code for proteins and have attracted remarkable interest because of their involvement in malignancies. Previous studies have proven that some lncRNAs contribute to the development and clinical outcome of AML. Our study constructed a risk stratification system for AML that will facilitate the prediction of clinical outcomes. Material/Methods We acquired the expression profiles of lncRNAs from the TCGA database to examine their role in the clinical outcomes of AML. We designed and validated a prognostic signature-based risk score system using a sample splitting approach and Cox regression analysis to elucidate the relationship between the clinical outcomes of AML and lncRNAs. Results We selected 10 lncRNAs to predict the clinical outcome of AML and were able to successfully predict the survival of patients with AML using this 10-lncRNA expression signature. Conclusions We developed a 10-lncRNA expression signature to predict the clinical outcome of AML. This approach demonstrates remarkable prognostic and therapeutic potential for AML.

antisense long non-coding rnas (aS lncrnas) have been increasingly recognized as important regulators of gene expression and have been found to play crucial roles in the development and progression of tumors. The present study explored the roles of aS lncrna ZnF710-aS1-202 in clear cell renal cell carcinoma (ccrcc). The expression levels of ZnF710-aS1-202 were detected in 46 human ccrcc tissues and 34 healthy adjacent renal tissues. The associations between the levels of ZnF710-aS1-202 expression and the clinicopathological features of the patients were evaluated by the χ 2 test. Gain-and loss-of-function experiments were performed to analyze the role of ZnF710-aS1-202 in ccrcc cell proliferation and survival in vitro. reverse transcription-quantitative Pcr and/or western blotting were employed to detect ZNF710-AS1-202, zinc finger protein 710 (ZNF710) and cyclin B1 expression. The cell counting Kit-8 and colony formation assays, as well as flow cytometry, were used to detect cell proliferation or apoptosis. The subcellular localization of ZNF710-AS1-202 was analyzed by RNA fluorescence in situ hybridization. The results revealed that ZnF710-aS1-202 was downregulated in human ccrcc tissues and was associated with the pathological grade, tumor size, local invasion and TnM stage, but not with lymph node metastasis or distant metastasis. However, ZnF710-aS1-202 overexpression promoted the proliferation of rcc cells and inhibited apoptosis. opposite results were observed when ZnF710-aS1-202 was knocked down by small interfering rna. Furthermore, ZnF710-aS1-202, which was mainly expressed in the cytoplasm of rcc cells, regulated ZnF710 mrna and protein expression in opposing manners. in conclusion, the present study revealed that ZnF710-aS1-202 and ZnF710 may serve as promising therapeutic targets for ccrcc.

No abstract

The human embryonic stem cell (hESC) line NERCe002-A-1 was generated through lentiviral transduction of the original NERCe002-A-1 hESC line with Zoanthus sp. green fluorescent protein (ZsGreen). Cells that expressed ZsGreen showed a >8.6-fold increase in fluorescence intensity compared with that of cells that expressed enhanced green fluorescent protein. The fluorescent hESC line can aid in identification of biological characteristics in vitro and in vivo by tracking cell growth, migration, and differentiation. Characteristic tests confirmed that the NERCe002-A-1 cell line expressed typical markers of pluripotency and had the capability to form the three germ layers in vivo.

The human embryonic stem cell line NERCe002-A-2 was generated by transduction of NERCe002-A cells with an expression vector carrying the luciferase gene. The stem cells labelled with luciferase can be transplanted into animals and detected by the bioluminescence imaging technology. This provides optimal prospects of application to in vivo stem cell tracing. Luciferin served as a substrate to detect the activity of luciferase, and luciferase expression was measured by quantitative PCR. Characterization assays suggested that the NERCe002-A-2 cell line expresses typical markers of pluripotency and can form the 3 germ layers in vivo.